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AMERICAN TEGUMENTARY LEISHMANIASIS: LANGERHANS CELLS IN MONTENEGRO SKIN TEST
Marcia Ferraz Nogueira(1), Mírian N. Sotto(2) & Luiz Carlos CuCé(3)
SuMMarY
This work analyzed the histopathology and epidermal Langerhans cells (LC) of Montenegro skin test (MST) in patients with 
American tegumentary leishmaniasis (ATL) in order to in situ characterize and compare the immunological reaction of the two major 
clinical forms of ATL, localized cutaneous leishmaniasis (LCL) and mucocutaneous leishmaniasis (MCL). MST histopathology of 
both LCL and MCL showed superficial and deep perivascular inflammatory infiltrate composed mainly of lymphocytes and histiocytes. 
Epidermal LC population was higher in MST biopsies taken from LCL patients when compared to MCL group, at 48 and 72 hours 
after antigen inoculation. Increased number of epidermal LC displayed in MST biopsies of LCL patients represents specific cellular 
immunity against parasites. The decrease of LC in MST biopsies of MCL patients does not necessarily indicate a worse specific 
cellular immunity in this clinical form of leishmaniasis.
KeYWorDS: Cutaneous leishmaniasis; Delayed type hypersensitivity; Immunopathology; Skin; Langerhans cells.
iNtroDuCtioN
Leishmaniasis is an infectious disease caused by the protozoan 
genus Leishmania. It is a zoonosis in which man act as incidental host. 
Leishmania is an obligate intracellular parasite of vertebrate hosts, and 
requiring an invertebrate vector, from Class Insecta- phlebotomine sand 
fly species to complete its vital cycle12.
American tegumentary leishmaniasis (ATL) affects the skin and 
mucosa. The most frequent forms in the state of São Paulo are localized 
cutaneous leishmaniasis (LCL) and mucocutaneous leishmaniasis (MCL). 
LCL is characterized by skin ulcers with infiltrated erythematous borders, 
with coarse and secreting granulose base, specially located in exposed 
areas of the body. MCL is characterized by ulcerated and infiltrated 
lesions in oral, nasal, pharyngeal and laryngeal mucous membranes, with 
compromise of the skin surrounding the nasal mucosa. Mucosal lesions 
appear two or more years after the healing of skin ulcer. The development 
of these forms of the disease depends on the host’s immune system and 
the species of Leishmania12.
The diagnosis of ATL is confirmed by the demonstration of the 
parasite in the lesions. The parasites are frequently scarce, and difficult 
to find in the lesions. In these cases the Montenegro skin test (MST) is 
useful to confirm the diagnosis of the disease14. 
MST consists of intradermal injection of 0.1 mL of a suspension 
with 3-4.5 × 106 dead promastigotes. The positive result to this test 
is considered the expression of cellular immunity of the host to the 
parasite14.
Immunity depends on both the host immune system and Leishmania 
species. The immune response against Leishmania may be effective 
enough to protect host from the development of disease. Otherwise, 
effective immunity is present in LCL. Exacerbated immunity is the cause 
of destructive and recurrent mucosal lesions. Non effective immunity 
leads to anergy with disseminated skin lesions3,4,10,12. 
MST is a delayed hypersensitivity reaction, characterized by type IV 
immune response, mimicking the granulomatous inflammatory reaction 
that occurs in leishmaniotic lesions3-5,9-12,14,15. All patients with LCL and 
MCL exhibit positive MST. The sensitivity and specificity of MST range 
from 83.7 to 100%. MST remains indefinitely positive, even after the cure 
of the disease. However, this concept was questioned by other authors. 
MST intensity is greater in patients that present long lasting disease and 
MCL form of the disease. The aggressiveness of MCL is related to the 
intensity of MST. However, exacerbated responses (with papule greater 
than 10 mm in diameter) are not exclusive of MCL3,5,9,10,12,14.
The purpose of this study was to analyze MST in LCL and MCL, 
by assessing and comparing the intensity of reaction, histological 
features and quantification of Langerhans cells, in an attempt to identify 
immunological differences between these two clinical forms of the 
disease.
MateriaL aND MetHoDS
The casuistic comprehends four LCL and six MCL patients 
followed up at the University of S. Paulo Medical School - Division of 
Dermatology. The study was approved by the research ethics board of 
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the Institution. Informed consent was obtained from all patients. The 
patients were male, with age ranging from 19 to 82 years (mean 49.9 
years). Nine patients were from different regions of Brazil and one from 
Bolivia (patient 3). 
The diagnosis of leishmaniasis was confirmed by positive MST, 
anti-Leishmania antibody demonstrated by indirect immune fluorescence 
and/or ELISA assay, and demonstration of parasites in lesions 
smears or biopsy exam with Leishmania antigen demonstration by 
immunoperoxidase technique16. 
Montenegro skin test: All patients were subjected to an intradermal 
injection of 100 µL of dead Leishmania promastigotes suspension (2 to 
3×106 parasites, called Montenegro antigen, produced at Adolfo Lutz 
Institute, in São Paulo, Brazil) for three times (at the same day) in three 
randomly selected points located on the right and left arms. 
The clinical evaluation of MST was made 72 hours after inoculation. 
The results were expressed by the two diameters of the papules or 
nodules. The mean of the two diameters were calculated for statistical 
analysis. MST was considered positive when the diameter of the resulting 
erythematous papule/nodule was ≥ 5 mm.
Histopathology: Skin biopsies were obtained in the centre of the 
erythematous papule, using 4 mm punch, under local anesthesia with 
2%, xylocaine, after the clinical evaluation of MST. Four samples were 
taken from each patient. The first biopsy was taken 24 hours after antigen 
inoculation; the second one, after 48 hours and the third one, after 72 hours. 
The fourth biopsy was taken from normal skin for control purposes. Each 
skin fragment was cut in two. One was fixed in 10% formalin and processed 
to histopathological exam. The other fragment was snap frozen and 
preserved in liquid Nitrogen until processed to immunohistochemistry.
Demonstration of Langerhans Cells by immunohistochemical 
technique: Five µm fragments of each biopsy were cut in cryostat 
and fixed in acetone, incubated with mouse monoclonal anti-CD1a 
antibody (Dako, NA 1/34 code M721, Carpinteria, CA, USA) and 
treated by avidin-biotin method modified as previously described. The 
reaction was developed using 0.06% hydrogen peroxide and 0.3 mg/mL 
3,3’-diaminobenzidine (Sigma Chemical, USA) in phosphate buffered 
saline and nickel chloride. Counterstaining was performed with methyl 
green. The Langerhans cells were immunolabeled in black color. 
Quantification of Langerhans cells: Epidermal CD1a immunolabeling 
area (Langerhans cells) were measured with image analysis system 
(Quantimet 500 Color System Qein V02.00A, Leica Cambridge Ltd.) 
using a microcomputer 486DX 33 equipped with multimedia video 
interface with a microscope (Leica Diastar) and video camera (JVC 
TK-1280V-color). Five random epidermal fields (×200 magnification), 
excluding stratum corneum and basal layer, were evaluated for each 
biopsy. The results were expressed in µm2.
Statistical analyses: The MST evaluation results at 24, 48 and 72 
hours post antigen inoculation were compared by chi square test. 
The results of Langerhans cells evaluation of normal skin and MST 
biopsies of LCL and MCL patients, as well as MST biopsies of both 
group of patients were compared by Mann-Whitney test. 
The level of significance was set at p ≤ 0.05.
reSuLtS
Intensity of Montenegro Skin Test: MST in LCL patients, at 24, 48 
and 72 hours, exhibited papule or nodule with mean area of 100, 25, 49 and 
100 mm2 respectively. In MCL group MST mean area of the three antigen 
inoculation sites were 225, 100, 196 and 100 mm2, respectively. The intensity 
of MST in LCL was lower than in MCL (p < 0.05) (see Table 1).
Histopathology of MST: Twenty nine MST skin biopsies were 
analyzed: 12 of LCL and 17 of MCL patients. The biopsy taken at 48 hour 
after antigen inoculation of case 6 was excluded because the specimen 
was insufficient for the analysis. 
The skin biopsies of MST revealed microscopic alterations in all 
assessed times (24, 48 and 72 hours) in both LCL and MCL groups. The 
epidermis showed acanthosis, spongiosis, basal cells vacuolar alteration 
and lymphocytic exocytosis. Less frequently, apoptosis, epidermal 
vesiculation, exulceration and necrosis were also seen.
Superficial and superficial and deep perivascular inflammatory 
infiltrate, composed lymphocytes and histiocytes, and a few of neutrophils 
and eosinophils, were the main dermal alteration. The 72 hours post 
antigen inoculation samples presented the most severe alterations. 
Necrosis was observed in 75% of LCL patients and in 50% of MCL 
specimens. Granulomatous reaction, with mild clusters of epithelioid 
cells, was observed in 83% of the samples of MCL and in only one 
specimen of LCL group. Interstitial edema, leukocytoclasia and vasculitis 
were observed in few specimens.
Demonstration, quantification and comparison of Langerhans cells 
in MST: The control skin of both groups displayed immunostained LC with 
anastomosing dendrites in epidermal spinous layer, intermingled between 
keratinocytes. MST biopsies at 24 hours after antigen inoculation, of LCL 
and MCL patients did not differ from control skin. At 72 hours post antigen 
inoculation, MST of LCL patients exhibited numerous LC, distributed 
among spinous layer keratinocytes. MCL specimens, taken at 48 and 72 
hours after antigen inoculation, displayed few LC in comparison to normal 
skin. These cells exhibited short and irregular dendrites.
Results of the quantification of Langerhans cells in MST biopsies of 
LCL and MCL groups, expressed by CD1a immunolabeled epidermal 
area, are demonstrated in Table 2. 
table 1 
 Intensity of Montenegro skin test in localized cutaneous leishmaniasis (LCL) 
and mucocutaneous leishmaniasis (MCL) (mm2)
Groups 
n = number of cases
LCL 
n = 4
MCL 
n = 6
Mean ± Standard 
deviation
68.5 ± 37.7 157.7 ± 64.0
p < 0.05*Range 25 - 100 100 - 225 
Median 74.5 148
*c2 test.
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Epidermal Langerhans cells population in MST biopsies of LCL 
group, taken at 72 hours after antigen inoculation, differed from normal 
skin (p ≤ 0.05). In the MCL group, there were statistically significant 
differences between normal skin LC population at 48 hours (p ≤ 0.001) 
and 72 hours (p ≤ 0.001) post antigen inoculation biopsies.
Langerhans cells population was higher in MST biopsies of LCL 
patients (at 48 and 72 hours after inoculation) when compared to MST 
specimens of MCL patients (p ≤ 0.001). 
DiSCuSSioN
MST is a cellular immune reaction of delayed hypersensitivity9,10. 
This reaction presents high sensitivity in patients with ATL, with current 
or past infection. Its positive score ranges from 82.4% to 100%. MST 
is considered a generic group-specific reaction, since patients with ATL 
develop positive response to antigens of different species of Leishmania 
and to antigens of protozoan genus Trypanosoma. The positive result of 
the reaction express the effectiveness of cellular immunity in LCL and 
MCL forms of the disease. Whereas MST is negative in diffuse (anergic) 
form of ATL3,5,9,10,12,14.
Positive MST in subjects of endemic areas that do not present 
history or signs of past disease indicates subclinical infection. Positive 
reactions in patients with leishmaniasis may reflect the development of 
host cellular immunity, which indicates protection to potential recurrence 
of the disease or new infections4,10,12.
In the present study, we observed a significant difference (p ≤ 0.05) 
between MST intensity in LCL and in MCL patients. In MLC patients 
MST exhibited higher intensity. Otherwise two (50%) LCL patients 
presented MST with 10 mm papule, which is considered strongly 
positive result9,10. 
Intensity of MST is determined by host characteristics that 
comprehend the type and number of lesions, duration of active disease 
and time up to cure. It is considered also a reflection of the patient’s 
degree of cellular immunity. The most intense reactions are expression 
of an exacerbated cellular immunity. This event is observed in patients 
with MCL who developed more aggressive lesions. This feature could 
be explained by the hyper reactive response. Patients with LCL present 
immunity against Leishmania, developing skin lesion, which may 
progress to spontaneous healing. MCL patients acquire protective 
immunity against Leishmania, but it is not enough to protect them from 
severe mucocutaneous lesions9,10.
There is disagreement in the literature concerning the intensity of 
MST. This is due to the fact that there is no standardized and reliable 
methodology to measure the intensity of the reaction. 
Histopathology of Montenegro Skin Test: The histopathological 
alterations observed in skin biopsies of MST taken 24, 48 and 72 hours 
after the antigen inoculation exhibited similar features in both LCL and 
MCL patients. These histopathological features were similar to those 
described by other authors10,15.
Langerhans cells in Montenegro Skin Test: As Langerhans cells 
quantification in normal epidermis varies according to anatomical 
location11, the normal skin control group was taken from the same body 
area as the MST specimens. 
We observed a higher LC population in MST epidermis of LCL patients 
within 72 hours after antigen inoculation when in comparison to normal skin 
(p = 0.05). In MCL group the LC population at MST taken 48 and 72 hours 
post antigen inoculation, was lower than in normal skin group (p = 0.001).
LCL presents increased LC in the cutaneous lesions. In DCL lesions 
there is a reduction of those cells in comparison to LCL. Otherwise the 
number of LC in DCL is higher than in normal skin. MCL presents 
absence of epidermal LC in its lesions7,8,17,18.
The role of LC in experimental and human tegumentary leishmaniasis 
has been widely studied13,20. LC plays a key role in antigen presentation 
and is capable of phagocytize the parasite1,2. 
The obtained data on MST of LCL patients, in which we detected an 
increase of epidermal LC, were in agreement to previously description on 
tuberculin reaction11. In MST of MCL patients LC were reduced in the 
epidermis. Their migration to dermis may be due to an attempt to start the 
cellular immune response of MCL, as demonstrated to tuberculin reaction 
of lepromatous patients previously sensitized to M. tuberculosis11. 
LC is essential to trigger and maintaining cellular immune response13. 
It may explain why LC are absent in MCL lesions. The absence of these 
cells results in development of chronic and destructive lesions observed 
in this form of leishmaniasis3,17.
table 2 
 Langerhans cells disclosed by CD1a epidermal expression (µm2) in localized cutaneous leishmaniasis (LCL) and mucocutaneous leishmaniasis (MCL)
Groups Normal skin 24 hours after antigen 
inoculation
48 hours after antigen 
inoculation
72 hours after antigen 
inoculation
LCL Mean ± SD 370.2 ± 237.5 341.9 ± 136.6 399.0 ± 131.4 606.8 ± 299.1
Range 73.3 – 1191.9 162.8 – 708.1 181.4 – 667.1 134.1 – 1316.8
Median 297.7a 320.6 398.6b 630.4c
MCL Mean ± SD 360.5 ± 146.1 294.4 ± 131.5 161.5 ± 91.4 125.1 ± 97.1
Range 127.7 – 636.7 63.6 – 585.8 40.8 – 359.8 0 – 358.4
Median 335.8d 296.8 146.8e 93.7f 
SD: standard deviation; a < c (p < 0.05); d > e (p < 0.001); d > f (p < 0.001); b > e (p < 0.001); c > f (p < 0.001) - Mann-Whitney test.
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Our study demonstrated and quantified LC in MST biopsies in an 
attempt to better analyze the reaction. It is important to keep in mind that 
MST and the granulomatous reaction of leishmaniasis are examples of 
delayed hypersensitivity reaction. Thus, it is possible to make an analogy 
of LC behavior in MST and in leishmaniotic lesions.
Even though some authors have stated that both LCL and MCL 
present cellular immunity, our study adds that the in situ cellular immune 
response expressed by MST is different in LCL and MCL.
MCL patients displayed reduction of Langerhans cells in MST 
biopsies. This result is similar to what is observed in the lesions of this 
form of disease. These data suggest that MCL cellular immune response 
is different from LCL, especially at the beginning of the defense process. 
At 48 hours after antigen inoculation MCL patients presented decrease of 
LC in comparison to normal skin. This event was not observed in LCL 
group. This observation may represent an early immunological process 
in MLC. However, it is still to be defined if this early immune response 
is effective against the parasite. 
The obtained data suggest that the quantification of Langerhans cells 
in MST is a tool to characterize differences in specific cellular immunity 
of LCL and MCL. It is better to display these differences than only 
evaluating the intensity and/or the histopathology of MST.
reSuMo
Leishmaniose tegumentar americana: células de Langerhans na 
reação intradérmica de Montenegro
Este trabalho analisou e quantificou as células de Langerhans e as 
características histopatológicas da reação de Montenegro nos pacientes 
com leishmaniose tegumentar americana (LTA) para caracterizar seu 
comportamento imunológico nas duas formas clínicas mais comuns da 
LTA, a leishmaniose cutânea localizada (LCL) e a leishmaniose cutâneo-
mucosa (LCM). O exame histopatológico apresentou infiltrado inflamatório 
perivascular superficial e profundo, com predomínio de histiócitos e 
linfócitos, sem diferença significante entre as duas formas da doença. O 
resultado da quantificação das CL apresentou aumento das CL na LCL e 
diminuição na LCM em 48 e 72 horas após a inoculação do antígeno (p 
< 0,001). O aumento das células de Langerhans epidérmicas na reação de 
Montenegro da LCL demonstra a presença de imunidade celular específica, 
enquanto a diminuição das mesmas células na LCM não necessariamente 
demonstra uma diminuição da imunidade celular específica. 
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